ESSA Pharma (NASDAQ:EPIX) fell above 18% premarket on Wednesday after the company revised terms of its merger with biotech firm XenoTherapeutics, lowering expected shareholder payout due to potential liabilities and updated cash estimates. Under the amended agreement, ESSA shareholders are now ...

Accessibility StatementSkip Navigation Shareholders expected to receive approximately $0.12 per share in cash upon closing of transaction and up to approximately $0.14 per CVR under revised terms Further Adjourns Special Meeting to October 3, 2025 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 24, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that it has reached an agreement to amend its previously announced Business Combination Agreement (the "Amended ...

TOKYO and GUANGZHOU, China, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd. (Riken Genesis) and Burning Rock Biotech Limited (NASDAQ: BNR, “Burning Rock”) today announced that the OncoGuide™ OncoScreen™ Plus CDx System based on OncoScreen™ Plus to be used as a companion diagnostic for AstraZeneca’s capivasertib has received Manufacturing and Marketing Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW). The CDx System is a combination medical device consisting of the OncoGuide™ O ...

PresentationAndrew FeinH.C. Wainwright & Co, LLC, Research Division Good morning, everyone. I'm Andrew Fein. I'm one of the biotechnology research analyst at H.C. Wainwright. It's my pleasure this morning to host a HCW @ Home event, even though many of you probably are not at home, with Quince Therapeutics. Here from the company are its CEO and Chief Medical Officer, Dirk Thye; and Brendan Hannah, its Chief Operating Officer and Chief Business Officer. So thank you both very much for being here this mornin ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Jasper Therapeutics, Inc.  (“Jasper” or the “Company”) (NASDAQ: JSPR) and certain officers.  The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-08010, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Jasper securities between November 30, 2023 ...

九价HPV疫苗研发进展 - 公司九价HPV疫苗Ⅲ期临床研究工作持续开展中 [1] - 在研疫苗研发若有实质性和阶段性进展会及时披露 [1]

After-hours trading on Tuesday featured a wave of notable price moves across the biotech and therapeutics space, with several small- and mid-cap names posting sharp gains following clinical updates, strategic announcements, or upcoming trial milestones. While regular session activity was mixed, post-market momentum reflected renewed attention to pipeline developments and near-term catalysts. Below is a roundup of key after-hours gainers.Shares of Cyclerion Therapeutics, Inc. (CYCN) surged 48.01% in after-h ...

WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”), a clinical-stage immuno-oncology company, today announces for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2022 (the “Irish Takeover Rules”), that it has published the definitive proxy statement of Mural relating to the Acquisition described below, which also constitutes a scheme circular under Irish law (the “Proxy Statement”) and that Mural has commenced mailing the Pr ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been roughly five months since my previous Regeneron Pharmaceuticals (NASDAQ: REGN ) article , where I discussed how Regeneron was still a “biotech juggernaut” thanks to their key brands of Dupixent, EYLEA, and Libtayo performing well, while other ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 23, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating 89bio, Inc. (NASDAQ: ETNB) related to its sale to Roche Holdings, Inc. Under the terms of ...